These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 7539179)

  • 21. Serum-to-urinary prostate-specific antigen ratio in patients with benign prostatic hyperplasia and prostate cancer.
    Hillenbrand M; Bastian M; Steiner M; Zingler C; Müller M; Wolff JM; Seiter H; Schuff-Werner P
    Anticancer Res; 2000; 20(6D):4995-6. PubMed ID: 11326656
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
    Mikolajczyk SD; Rittenhouse HG
    Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Tumor markers in prostate cancer].
    Kuriyama M
    Gan To Kagaku Ryoho; 1994 Sep; 21(12):1915-22. PubMed ID: 7521999
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate cancer detection in BPH patients.
    Puppo P; Perachino M; Ricciotti G; Bozzo W
    Arch Esp Urol; 1994 Nov; 47(9):867-72. PubMed ID: 7530942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of patient age on the serum PSA concentration. An important clinical observation.
    Oesterling JE; Cooner WH; Jacobsen SJ; Guess HA; Lieber MM
    Urol Clin North Am; 1993 Nov; 20(4):671-80. PubMed ID: 7505975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Status of PSA determination for early detection of prostate carcinoma].
    Hammerer P; Huland H
    Versicherungsmedizin; 1995 Jun; 47(3):83-6. PubMed ID: 7541925
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is there a link between BPH and prostate cancer?
    Chang RT; Kirby R; Challacombe BJ
    Practitioner; 2012 Apr; 256(1750):13-6, 2. PubMed ID: 22792684
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Clinical significance of prostate-specific antigen].
    Tveter KJ; Otnes B
    Tidsskr Nor Laegeforen; 1994 Jan; 114(2):160-2. PubMed ID: 7510073
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Free, complexed and total serum prostate specific antigen: the establishment of appropriate reference ranges for their concentrations and ratios.
    Oesterling JE; Jacobsen SJ; Klee GG; Pettersson K; Piironen T; Abrahamsson PA; Stenman UH; Dowell B; Lövgren T; Lilja H
    J Urol; 1995 Sep; 154(3):1090-5. PubMed ID: 7543605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Significance of the PSA-concentration for the detection of prostate cancer].
    Stachon A
    Pathologe; 2005 Nov; 26(6):469-72. PubMed ID: 16195861
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
    Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
    Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation of benign prostatic hyperplasia and prostate cancer employing prostatic-specific antigen density.
    Wolff JM; Scholz A; Boeckmann W; Jakse G
    Eur Urol; 1994; 25(4):295-8; discussion 304. PubMed ID: 7519991
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Prostate-specific antigen in patients with benign prostatic hyperplasia].
    Goncalves F; Kausitz J; Bárdos A; Miklosi M
    Rozhl Chir; 1994 Sep; 73(6):291-3. PubMed ID: 7536350
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia .
    Filella X; Alcover J; Molina R; Corral JM; Carretero P; Ballesta AM
    Prostate; 2000 Feb; 42(3):181-5. PubMed ID: 10639188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prostatic cancer and BPH.
    Brown SA
    Postgrad Med; 1994 Jul; 96(1):24-5. PubMed ID: 7517542
    [No Abstract]   [Full Text] [Related]  

  • 36. [PSA in prostatic fluid].
    Lehmann K; Simmler F; Schmucki O; Hauri D
    Urologe A; 1994 May; 33(3):232-4. PubMed ID: 7519804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostate-specific antigen: an evaluation 15 years after its discovery].
    Janssen T; Schulman C
    Prog Urol; 1994 Apr; 4(2):171-80. PubMed ID: 7515305
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Value of intravenous urography versus ultrasound in preoperative assessment of prostatic hyperplasia].
    Böss HP; Knönagel H
    Ultraschall Med; 1992 Oct; 13(5):228-33. PubMed ID: 1279799
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Additional aids in detection of prostate carcinomas? PSA-prostatic volume quotient, PSA-doubling time, age-dependent PSA reference values and PSA in urine].
    Pannek J; Brands FH
    Urologe A; 2000 Jul; 39(4):324-9. PubMed ID: 10957773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Glycosylation of prostate specific antigen and its potential diagnostic applications.
    Vermassen T; Speeckaert MM; Lumen N; Rottey S; Delanghe JR
    Clin Chim Acta; 2012 Oct; 413(19-20):1500-5. PubMed ID: 22722018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.